ProKidney Corp.
PROK
$0.09
Change (1 day)
$4.44
Year High
$1.18
Year Low
Categories
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp. (PROK) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.38 M | -56,236,000 | 29.22 M | 420.55 M | 374.15 M |
| 2022 | -487,853,000 | 13.06 M | 518 M | 504.72 M | |
| 2021 | -19,224,000 | 13.38 M | 40.3 M | 27.27 M | |
| 2020 | -3,019,000 | 6.84 M | 16.7 M | 5.59 M | |
| 2019 | -14,216,000 | 3.72 M | 19.61 M | 15.42 M |